AMGN · Earnings call · 2026Q3T · Full report

Acquisition / Partnership / Divestiture

AMGEN INC · 2026-11-03 · Importance 16 · Surprise 6

Management said Amgen’s business-development focus remains on opportunities aligned with its four therapeutic areas of focus and its goal of consistent long-term growth. The CEO noted that a meaningful portion of revenue comes from licensed or acquired molecules and expects that to remain true over time. He emphasized disciplined internal and external capital allocation and seeking external opportunities that offer a return for Amgen shareholders.

Key facts

• Amgen said a meaningful portion of its revenues came from molecules it licensed or acquired and expected that to continue over time.
• Amgen said its business development focus was on opportunities aligning with its 4 therapeutic areas of focus.